Response of resistant melanoma to a combination of weekly paclitaxel and bevacizumab.
We report here a taxol-bevacizumab-responsive metastatic melanoma case. Although the patient had been heavily pretreated for two years, she did not show any stabilisation or objective response of her disease. After treatment with taxol and bevacizumab combination an impressive response was obtained.
González Cao
M
M
Oncology Department, Clínica Universitaria de Navarra, C/Pio XII s/n, 31008 Pamplona, Spain. mgocao@unav.es
Viteri
S
S
Garrán
C
C
Nieto
Y
Y
Aristu
J
J
Ponz
M
M
Martín Algarra
S
S
D000328:Adult; D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D000068258:Bevacizumab; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D008545:Melanoma / Q000188:drug therapy*; D017239:Paclitaxel / Q000008:administration & dosage*; D012074:Remission Induction; D012878:Skin Neoplasms / Q000188:drug therapy*
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000972:Antineoplastic Agents, Phytogenic; D000068258:Bevacizumab; D017239:Paclitaxel